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ABSTRACT
Objective: To determine the potential of opportunistic
glycated haemoglobin (HbA1c) testing of pathology
samples to detect previously unknown diabetes.
Design: Pathology samples from participants collected
for other reasons and suitable for HbA1c testing were
utilised for opportunistic diabetes screening. HbA1c
was measured with a Biorad Variant II turbo analyser
and HbA1c levels of ≥6.5% (48 mmol/mol) were
considered diagnostic for diabetes. Confirmation of
previously unknown diabetes status was obtained by a
review of hospital medical records and phone calls to
general practitioners.
Setting: Hospital pathology laboratory receiving
samples from hospital-based and community-based
(CB) settings.
Participants: Participants were identified based on
the blood sample collection location in the CB,
emergency department (ED) and inpatient (IP) groups.
Exclusions pretesting were made based on the
electronic patient history of: age <18 years, previous
diabetes diagnosis, query for diabetes status in the
past 12 months, evidence of pregnancy and sample
collected postsurgery or transfusion. Only one sample
per individual participant was tested.
Results: Of the 22 396 blood samples collected, 4505
(1142 CB, 1113 ED, 2250 IP) were tested of which
327 (7.3%) had HbA1c levels ≥6.5% (48 mmol/mol).
Of these 120 (2.7%) were determined to have
previously unknown diabetes (11 (1%) CB, 21 (1.9%)
ED, 88 (3.9%) IP). The prevalence of previously
unknown diabetes was substantially higher (5.4%) in
hospital-based (ED and IP) participants aged over
54 years.
Conclusions: Opportunistic testing of referred
pathology samples can be an effective method of
screening for diabetes, especially in hospital-based and
older persons.
INTRODUCTION
Diabetes is an important and common
disease with signiﬁcant morbidity and mortal-
ity.1 Its worldwide prevalence in 2010 was
estimated to be 285 million, and this was
expected to increase to 439 million in 2030.2
More than 90% of those affected have type 2
diabetes.1 In 2000 in Australia, the
prevalence of diabetes in persons ≥25 years
old was 7.5%, and importantly, half of those
with diabetes had not been diagnosed prior
to the survey.3
The high prevalence of undiagnosed type
2 diabetes is due to the insidious nature of
its onset. The delay in clinical diagnosis of
type 2 diabetes has been estimated to be at
least 5–7 years.4 This is of clinical relevance
as microvascular and macrovascular compli-
cations are often already present at the time
of diagnosis.4–6 As the association between
hyperglycaemia and the development of ret-
inopathy is very strong, the presence of this
complication at the time of diabetes diagno-
sis is very likely a consequence of the prior
undiagnosed diabetes.7 Even though hyper-
glycaemia is associated with a greater risk of
macrovascular disease events, the causative
role of hyperglycaemia in these complica-
tions is less clear.8 9 Nevertheless, the UK
Prospective Diabetes Study showed that
better glycaemic control in type 2 diabetes
patients over 10 years reduced microvascular
complication rates and, with longer term
follow-up, macrovascular events and death
from any cause.10 11 Thus, early detection
and treatment of type 2 diabetes has the
potential to signiﬁcantly reduce the morbid-
ity and mortality associated with this disease.
However, there has been recent debate relat-
ing to the cost-beneﬁt analysis of diabetes
ARTICLE SUMMARY
Strengths and limitations of this study
▪ The strengths of this work are the large sample
size, the inclusion of separate community-based,
emergency department and inpatient groups,
and the rigourous methodology used to confirm
which subjects screening positive for diabetes
truly had previously unknown diabetes.
▪ A limitation of the study is that the design did
not allow for follow-up of outcomes for those
subjects identified with previously unknown dia-
betes after general practitioner notification of the
positive opportunistic HbA1c screening result.
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screening versus population-based health promotion
approaches to reduce risk.12 13
Recently, WHO, the American Diabetes Association
(ADA) and the National Health Scheme in the UK
endorsed the use of glycated haemoglobin (HbA1c) for
the diagnosis of diabetes14–16 and, recently, an Australasian
working party has similarly recommended the use of
HbA1c for diagnostic purposes.17 The recommendation is
that diabetes is diagnosed by an HbA1c level of ≥6.5%
(48 mmol/mol). ADA also endorsed the use of HbA1c in
the range of ≥5.7% and <6.5% (≥39 and <48 mmol/
mol)) for the diagnosis of prediabetes.15 This allows for
the development of new approaches to the screening for
diabetes. A US-based study showed that HbA1c could be
used to detect undiagnosed diabetes in hospitalised
patients.6 In a recent Australian study of hospitalised
patients using a diagnostic HbA1c cut-off of ≥6.5%,
undiagnosed diabetes was found in 11%.18
A major contributor to cost in screening programmes
is the organisation and collection of blood samples. In
this study, we used blood samples already available to
ACT Pathology (Canberra, Australian Capital Territory,
Australia) from referral for unrelated tests to assess
prevalence of undiagnosed diabetes using HbA1c. Three
separate groups were assessed: community-based patients
referred for pathology testing by family physicians (CB),
patients attending only the emergency department
(ED) and hospitalised inpatients (IP).
METHODS
Ethical considerations
This study was approved by the ACT Health Human
Research Ethics Committee. Approval without obtaining
participant consent was based on the recommendations
of Section 2.3.6 of the National Statement on Ethical
Conduct in Human Research (2007), particularly part b
“the beneﬁts of the research justify any risk or harm
associated with not seeking consent”, part c “it is imprac-
ticable to obtain consent” and part g “in case the results
have signiﬁcance for participants’ welfare there is, where
practicable, a plan for making information arising from
the research available to them”.19
Participants
ACT Pathology is a certiﬁed laboratory with the National
Glycohemoglobin Standardisation Program (NGSP) and
provides pathology testing services to acute hospital
patients (IP and emergency) and community patients.
HbA1c measurement requires a sample to be collected in
an EDTA tube, and this is the same sample that is required
for a full blood count (FBC). We used samples referred to
the laboratory for an FBC for our screening study. The
ACT Pathology Laboratory Information System (LIS) was
used to search for consecutive FBC samples from April
2010 to January 2011. There were some breaks in collec-
tion due to research assistant unavailability. A total of
22 396 FBC requests were identiﬁed and the pathology
electronic history for the respective participants was
exported into LabWizard (Paciﬁc Knowledge Systems,
Surry Hills, New South Wales, Australia). The participants
were separated into three groups according to the collec-
tion site of the samples: CB, ED and IP (ﬁgure 1).
Samples were excluded if they were duplicate samples
from the same participant, if the participant was
<18 years of age, if the participant was pregnant, or if
the participant was postsurgery or had had a transfusion.
Other exclusion criteria were any requests for HbA1c
testing in the previous 12 months, evidence of diabetes
screening by a glucose tolerance test or a glucose load
test in the previous 12 months, and a previous diagnosis
of diabetes identiﬁed from within the LIS from clinical
notes, results indicative of diabetes or requests for inves-
tigating diabetes. Samples from participants presenting
to ED who had a record of any pathology testing in the
previous 12 months were also excluded (ﬁgure 1).
Sample collection and HbA1c assay
Samples were collected after completion of the FBC ana-
lysis and stored at −80°C prior to HbA1c testing. Samples
that were not located or had insufﬁcient volume or were
visibly degraded were removed from the testing cohort
(ﬁgure 1). HbA1c was measured in 4505 samples using a
Biorad Variant II Turbo Analyser (Bio-Rad Laboratories
Pty, Ltd, Hercules, California, USA). The interassay coefﬁ-
cient of variation based on the NGSP HbA1c % values was
2.3% at an HbA1c of 5.15% and 1.7% at an HbA1c of
9.77%. Samples were not stored for a period longer than
6 months prior to being tested.
Diagnosis of unknown diabetes
From the tested samples, a diagnosis of diabetes was made
if the HbA1c was ≥6.5% (48 mmol/mol). To determine if
this diagnosis was previously known or unknown for the
respective individual, the hospital record (if available) was
searched and the family practitioner was contacted (by
phone) to determine the individual’s history.
Statistical analysis
HbA1c data are duly reported in the traditional NGSP
HbA1c % format and the SI unit mmol/mol as
endorsed by the International Federation of Clinical
Chemistry. The descriptive statistics used include the
means±SD, median, maximal and minimal as indicated.
An analysis of variance was conducted to investigate
age and gender determinants of the measured HbA1c
in the three patient groups. Age in years was included as
a linear effect, rather than as speciﬁc age categories,
because HbA1c was found to change in a smooth linear
fashion with age. This linear effect was allowed to vary
between men and women in the ﬁnal model. More ﬂex-
ible non-linear age effects, and formulations that
allowed differences in the age effect for the three
patient groups, were examined, but neither was found
to be supported by the data. The analysis was conducted
in the R statistical software.20
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Figure 1 Flow diagram showing the process involved in selecting full blood count (FBC) samples for opportunistic glycated
haemoglobin (HbA1c) testing and the overall testing results. Patients were divided into community-based (CB), emergency
department (ED) and inpatient (IP) groups based on origin of sample collection. Samples were excluded from testing according
to the reasons indicated (upper rectangular grey boxes). Of the patients tested, those found to have elevated HbA1c ≥6.5%
(≥48 mmol/mol) and to have previously known diabetes were excluded (lower rectangular box). The number of patients found to
have previously undiagnosed diabetes is shown in the lower rounded-edge boxes. LIS, laboratory inquiry system; GP, general
practitioner.
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RESULTS
A total of 22 396 samples suitable for HbA1c analysis were
received in the study time interval. After excluding
samples for the reasons listed above, HbA1c was measured
in 1142 CB, 1113 ED and 2250 IP samples (ﬁgure 1). A
total of 4505 HbA1c tests were performed, of which 327
(7.3%) had test readings of ≥6.5% (≥48 mmol/mol), con-
sistent with the diagnosis of diabetes. After examination of
the hospital record and/or contacting the family practi-
tioner, we had 120 cases (2.7% of total tested) of previ-
ously unsuspected diabetes. Of the 120 new cases of
diabetes, 11 (1%) were CB participants, 21 (1.9%) were
from the ED group and 88 (3.9%) were the hospital
IP group (ﬁgure 1).
Analysis of the tested cohort (known diabetes patients
removed) showed that the mean HbA1c levels were 5.4
±0.4% (36±5 mmol/mol) for CB, 5.5±0.5% (37
±5 mmol/mol) for ED and 5.6±0.5% (38±6 mmol/mol)
for IP participants (table 1). The CB and ED patients
were, respectively, an average of 7.4 and 9.7 years
younger than the IP patients (table 1). Considering that
HbA1c increased linearly with age (0.5% from ages 20
to 90; p<0.001), the HbA1c results were adjusted for age
difference between the groups. IP age-adjusted HbA1c
was still found to be greater than CB HbA1c (p<0.001).
Age-adjusted HbA1c results for ED patients were not dif-
ferent from those for the other groups. Besides age,
patient gender was also an important consideration,
with women having HbA1c results 0.13% less than men
(p<0.05). Also, the age-related increase in HbA1c is
more pronounced for men than for women (p<0.05).
Of note, age, gender and group only explained 12% of
the variability in HbA1c results.
Patients with a new diagnosis of diabetes were signiﬁ-
cantly older than the non-diabetic patients in each of
the tested groups and were more likely to be from the
ED and IP groups (tables 1 and 2). In fact, previously
undiagnosed diabetes was not detected at all in the CB
group less than 40 years of age compared with a rate
of 5.8% detection in the IP group over the age of 54
(table 2).
ADA has classiﬁed patients with HbA1c levels in the
range of 5.7–6.4% (39–47 mmol/mol) as having predia-
betes.15 Of the patients in our study, 24.8%, 28.7% and
39.5% of CB, ED and IP patients, respectively, had
HbA1c levels in this range (table 2).
DISCUSSION
Diabetes mellitus is an ideal condition to screen for, as it
fulﬁls all the principles of screening that need to be met
according to WHO.21 The challenge is to perform
regular screening of the population in a time-effective
and cost-effective manner. Population-based surveys,
including the AUSDIAB study in Australia, indicate that
about 50% of patients with diabetes have not been diag-
nosed.3 In this study, we investigated whether opportun-
istic diabetes screening through measuring HbA1c in
blood samples ordered for other reasons could assist in
uncovering some of these cases of undiagnosed
diabetes.
HbA1c levels were measured in samples from three
separate populations: community-based participants
being more likely to be relatively well and under con-
tinuing general practitioner care (CB); participants who
had attended only the emergency department in the last
Table 1 Patient age and HbA1c characteristics within tested community-based, emergency department and inpatient
participant groups*
Community-based (n=1126) Emergency (n=1061) Inpatient (n=2114)
Age (years)
Mean (±SD) 51.8 (±17.1) 49.5 (±20.5) 59.2 (±19.1)
Median 52 47 61
Range 18–92 18–98 18–97
HbA1c (%)†
Mean (±SD) 5.4 (± 0.4) 5.5 (± 0.5) 5.6 (±0.5)‡
Median 5.4 5.5 5.6
Range 3.7–8.9 4.0–10.3 3.2–12.2
HbA1c (mmol/mol)†
Mean (±SD) 36 (±5) 37 (±5) 38 (±6)‡
Median 36 37 38
Range 17–71 20–89 11–110
Mean (±SD) of age (years) of patients with HbA1c % (mmol/mol)
<5.7 (<39) 48.5 (±16.8) 44.2 (±18.8) 54.7 (±19.8)
5.7–5.9 (39–41) 60.7 (±13.6) 59.9 (±18.9) 63.4 (±17.8)
6.0–6.4 (42–47) 63.1 (±15.3) 64.1 (±19.5) 66.7 (±14.5)
≥6.5 (≥48) 59.5 (±10.2) 65.0 (±18.1) 67.7 (±15.6)
*Tested patients subsequently found to have previously known diabetes were excluded from this analysis.
†Data are dually reported in the traditional NGSP % haemoglobin and the new recommended IFCC mmol/mol format.
‡IP HbA1c results were found to be significantly greater than CB across the age range (p<0.001).
CB, community based; HbAlc, glycated haemoglobin; IP, inpatient.
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12 months (as far as our records showed) (ED); and hos-
pitalised participants reﬂecting a group of sicker indivi-
duals (IP). Efforts were made to eliminate testing
samples in participants who were likely to have already
been diagnosed with diabetes or who were likely to have
been screened for diabetes within the previous
12 months. It was anticipated that objective evidence of
undiagnosed diabetes mellitus might be quite different
between these three groups.
In the participants eventually tested, the rates of previ-
ously undiagnosed diabetes were 1%, 1.9% and 3.9% in
the CB, ED and IP groups, respectively. Despite efforts
to exclude testing samples from patients already with a
diagnosis of diabetes, 1.4%, 4.7% and 6.2% of the
patients in the three respective groups did have a previ-
ous diagnosis. Age was a major factor in determining
risk. Patients <40 years of age had rates of previously
unknown diabetes of 0%, 0.5% and 1.3% in the CB, ED
and IP groups, respectively, compared with 1.5%, 4%
and 5.8% in patients >54 years of age.
The family doctors of all the patients newly diagnosed
with diabetes in this study were notiﬁed such that con-
ﬁrmation of the diagnosis could occur and appropriate
care could be initiated. The action taken by the family
doctors, however, was not within the scope of this study.
Considering that WHO and ADA state that a single
HbA1c ≥6.5% (48 mmol/mol) is diagnostic of diabetes,
false-positive diagnoses should occur rarely. Therefore,
this method of screening should have a high-positive
predictive value.
Previous studies have also investigated the prevalence
of undiagnosed diabetes in a hospital setting. Wexler
et al6 from the USA found a comparable 5% of unsus-
pected diabetes in hospitalised patients using the cut-off
>6.5% (>48 mmol/mol). An Australian study from
Adelaide by Valentine et al17 found 11.1% of unsus-
pected diabetes, which is much higher than our results.
However, their methodology only tested HbA1c on those
with bloods taken at admission with a random plasma
glucose >5.5 mmol/L, so it is not truly representative of
hospital inpatients, rather representative of a group with
an expected higher positive rate of diabetes. This study
also was reliant on correct coding for diabetes on dis-
charge in order to exclude previously known diabetes.
For the current study, efforts to exclude previous dia-
betes were much more rigorous with careful review of
the hospital record, if available, and phone calls to the
patients’ family doctors.
The current study also differed from the previous
studies in that CB and ED patients not admitted to the
hospital were included. The rate of unknown diabetes in
the CB group was quite low at 1%. This is much lower than
Table 2 Patients within the HbA1c categories according to age within the tested community-based, emergency department
and inpatient groups*
Community-based Emergency Inpatient
Number [%] patients with HbA1c % (mmol/mol)†
Age <40 years
<5.7 (<39) 276 [92.9] 333 [88.1] 305 [80.5]
5.7–5.9 (39–41) 15 [5.1] 31 [8.2] 53 [14.0]
6.0–6.4 (42–47) 6 [2.0] 12 [3.2] 16 [4.2]
≥6.5 (≥48) 0 [0.0] 2 [0.5] 5 [1.3]
Total 297 [100] 378 [100] 379 [100]
Age ≥40 to <55 years
<5.7 (<39) 245 [79.0] 203 [72.2] 290 [63.5]
5.7–5.9 (39–41) 39 [12.6] 54 [19.2] 101 [22.1]
6.0–6.4 (42–47) 23 [7.4] 21 [7.5] 57 [12.5]
≥6.5 (≥48) 3 [1.0] 3 [1.1] 9 [2.0]
Total 310 [100] 281 [100] 457 [100]
Age 55 and above
<5.7 (<39) 317 [61.1] 200 [49.8] 595 [46.6]
5.7–5.9 (39–41) 135 [26.0] 111 [27.6] 345 [27.0]
6.0–6.4 (42–47) 59 [11.4] 75 [18.7] 264 [20.7]
≥6.5 (≥48) 8 [1.5] 16 [4.0] 74 [5.8]
Total 519 [100] 402 [100] 1278 [100]
All patients
<5.7 (<39) 838 [74.4] 736 [69.3] 1190 [56.3]
5.7–5.9 (39–41) 189 [16.5] 196 [18.5] 499 [23.6]
6.0–6.4 (42–47) 88 [7.8] 108 [10.2] 337 [15.9]
≥6.5 (≥48) 11 [1.0] 21 [2.0] 88 [4.2]
Total 1126 [100] 1061 [10] 2114 [100]
*Tested patients subsequently found to have previously known diabetes were excluded from this analysis.
†Data are duly reported in the traditional NGSP % haemoglobin and the new recommended IFCC mmol/mol format.
HbA1c, glycated haemoglobin.
Simpson AJ, Krowka R, Kerrigan JL, et al. BMJ Open 2013;3:e003411. doi:10.1136/bmjopen-2013-003411 5
Open Access
 group.bmj.com on November 11, 2013 - Published by bmjopen.bmj.comDownloaded from 
the rate of undiagnosed diabetes in the community-
based AUSDIAB cohort, but a proportion of the
AUSDIAB cohort would not have been engaged in regular
medical care.3 General practitioners predominantly care
for the CB patients of the current study such that the low
level of unsuspected diabetes in these patients may be indi-
cative of a high level of awareness of diabetes and screen-
ing by them within the ACT region. For this reason,
opportunistic pathology-based diabetes screening in this
group and in this locale may not be as rewarding as in the
other groups.
The ED group had twice the rate of unknown diabetes
compared with the CB group at 1.9%. An opportunistic
approach to diabetes screening may be much more rele-
vant to the ED group, as a higher proportion are quite
likely to not be engaged with routine care with a family
doctor. This group is also likely to include frequent
attendees to hospital with chronic illness, although
many of these patients would have been excluded
because of a record of other pathology testing in the
preceding 12 months. As expected, the IP group had
the highest rate of unknown diabetes at 3.9%.
An important contributor to any screening programme
cost is sample collection and data entry. The procedure
we describe removes these costs. In an opportunistic
screening, costs could also be reduced by enhanced-
computer systems to identify samples to be tested and
inclusion of the result in the routine pathology reporting
to the patients’ treating doctors. It has recently been
noted that screening for diabetes in the UK did not
reduce mortality at 10 years.22 23 However, intensive treat-
ment following diagnosis reduces complications and also
reduces mortality over a longer period.10
In conclusion, within this Australian setting, opportun-
istic diabetes screening using HbA1c on FBC samples
collected for other purposes is possible and cost-
effective. Patients presenting to the emergency depart-
ment or admitted to hospital and being older than
54 years of age are most likely to have previously
unknown diabetes. This method of diabetes screening
warrants further consideration.
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